Blood Res 2019; 54(2): 81-83
Chimeric antigen T cell receptor treatment in hematological malignancies
Natasha Ali, FCPS Haematology
Department of Pathology and Laboratory Medicine/Oncology, Aga Khan University, Karachi, Pakistan
Correspondence to: Natasha Ali, FCPS Haematology
Department of Pathology and Laboratory Medicine/Oncology, Aga Khan University, Karachi, Pakistan
Received: February 24, 2019; Revised: April 5, 2019; Accepted: April 28, 2019; Published online: June 30, 2019.
© The Korean Journal of Hematology. All rights reserved.

cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

The treatment of malignant hematological disorders is still challenging, particularly in cases of refractory diseases. Although hematopoietic stem cell transplantation is a potentially curative option, it has been associated with a transplant-related mortality rate of 20–25% [1]. The technique of adoptive T cell transfer has gained significant focus in the field of hematology in recent years. Chimeric antigen receptor T cell (CAR-T cell) therapy is a novel immunotherapy technique in which T lymphocytes are engineered with synthetic receptors known as the chimeric antigen receptors (CAR). This engineered effector CAR-T cell is capable of recognizing and eliminating cancer cells. It performs this function independent of the major histocompatibility molecules. CAR-T cell therapy is being used for the treatment of hematological malignancies, such as acute lymphoblastic leukemia, acute myeloid leukemia, lymphomas, and multiple myeloma.

With the advent of the use of retroviral vectors and T cell engineering, the first generation of CAR-T cells was developed in 1990 [2]. Due to their short half-life, the first generation of CAR-T cells was not very efficacious. However, almost a decade later, a co-stimulatory domain was developed, which set forth the development of second generation CAR-T cells and eventually, in 2003, a product targeting CD19 was developed [3]. In 2011, these CAR-T cells were successfully used in a patient with acute lymphoblastic leukemia. Currently, two therapies of US Food and Drug Administration (FDA) approved CAR-T cells are available, which include the use of axicabtagene ciloleucel (KTE-C19) and tisagenlecleucel (CTL019) [4]. Axicabtagene ciloleucel and tisagenlecleucel have been approved for relapsed/refractory conditions of Non-Hodgkin's lymphoma in young adults and B-acute lymphoblastic leukemia in pediatric and adult patients, respectively. The most recent data obtained from the ZUMA-1 study presented at the American Society of Clinical Oncology in 2018 showed that, after therapy, a complete response rate of 58% at 15.1 months was observed in patients with diffuse large B-cell lymphoma [5]. The efficacy data of the phase II single-arm study on tisagenlecleucel showed that a complete remission had occurred in 93% and 58% of patients at one month and twelve months, respectively [6].

Another ideal chimeric receptor antigen that has been focused upon in recent times for the treatment of multiple myeloma is the B cell maturation antigen (BCMA). BCMA or CD269 is the seventeenth member of the tumor necrosis factor superfamily (TNFRSF17) [7]. The main role of BCMA is to regulate B cell maturation and survival during their differentiation into plasma cells. It is ubiquitously expressed on members of the B cell lineages, which include plasmablasts and plasma cells, but not on hematopoietic stem cells and naïve B cells. In 2016, Kochenderfer et al. [8] reported the results of the first clinical trial conducted on humans on the safety and efficacy of second generation anti-BCMA-CAR with CD3/CD28 signaling domains. Twelve patients were enrolled in the study and received a single dose of CAR-BCMA T cells, which was subsequently escalated for four levels as follows: 0.3, 1, 3, and 9×106 CAR-T cells/kg body weight. Effective clinical responses were seen at higher dose levels (3 and 9×106 cells/kg). This trial provided evidence on the anti-myeloma activity of CAR-BCMA cells and opened avenues for subsequent trials to employ immunotherapy as a treatment option for multiple myeloma.

Based on the successful outcome of CAR-T cell therapy for B cell malignancies, various groups started working on cellular or antibody-based immunotherapies for acute myeloid leukemia (AML). The CD33 antigen, which is expressed on healthy myeloid and myeloid progenitor cells with 90% expression in myeloid leukemic blast cells, is a potential target for these immunotherapies. This antigen has been targeted previously when a humanized drug-conjugated anti-CD33 antibody (Gemtuzumab) was developed and approved by FDA in 2000 [9]. In 2010, it was withdrawn from the European and US markets due to resulting complications of bone marrow toxicity and veno-occlusive disease. However, it was reintroduced in 2018, after Hills et al. [10] published a meta-analysis suggesting that a low fractionated dose of Gemtuzumab in combination with chemotherapy had improved overall survival in patients with AML. Because of this response and the increased expression of CD33 on myeloid cells, many clinical trials are underway on anti-CD33 CAR therapy.

There has been considerable progress on the application of CAR-T cell therapy in recent decades, although, with associated toxicities. The maximum toxicity is observed in the cytokine release syndrome (CRS) associated with anti-tumor activity in which the patients may develop symptoms such as high-grade fever, hypoxia, hypotension or mild flu [11]. Another complication associated with this is the tumor lysis syndrome caused due to a rapid and massive destruction of cancer cells [12]. The macrophage activation syndrome is another life threatening complication resulting in systemic inflammatory response and pancytopenia with an unknown mechanism of action [13].

In order to decrease the toxicities associated with this therapy, the patients must undergo a thorough physical evaluation and its profile should include an assessment of cardiac function, bone marrow examination and graft versus host disease status. Tumor lysis protocol is started preemptively in patients with bulky disease. At the time of infusion, aggressive hemodynamic assessment and supportive care should be carried out by evaluating complete blood counts, metabolic panel, and markers for tumor lysis. Cytopenias resulting from CAR-T cell infusion can be managed with transfusion support and administration of growth factor. For the cytokine release syndrome, Tocilizumab (IL-6 receptor antagonist) is being used extensively as an off-label therapy in patients who have developed this catastrophic complication [14]. Other therapies for the treatment of CRS include the use of corticosteroids, siltuximab and etanercept.

The use of CAR-T cell therapy is the future in the treatment of hematological malignancies. Currently their role is limited to a refractory/relapsed setting but soon this option will be incorporated in treatment paradigms at multiple points. Adverse events include the development of CRS, which is still a challenge preventing its widespread use. Cutting-edge bench research is required to improve the effectiveness of this therapy that can provide physicians and patients a better chance at eradicating hematological cancers.

  1. Bartenstein M, Deeg HJ. Hematopoietic stem cell transplantation for MDS. Hematol Oncol Clin North Am 2010;24:407-422.
  2. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993;90:720-724.
  3. Sadelain M, Rivière I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003;3:35-45.
  4. Wohlfarth P, Worel N, Hopfinger G. Chimeric antigen receptor TXMLLink_XYZcell therapy-a hematological success story. Memo 2018;11:116-121.
  5. Locke FL, Ghobadi A, Jacobson CA, et al. Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma. J Clin Oncol 2018;36:abst 3003.
  6. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018;378:439-448.
  7. Mikkilineni L, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for multiple myeloma. Blood 2017;130:2594-2602.
  8. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigenreceptor-transduced T cells. Blood 2012;119:2709-2720.
  9. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001;7:1490-1496.
  10. Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 2014;15:986-996.
  11. Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 2018;15:47-62.
  12. Ataca P, Arslan Ö. Chimeric antigen receptor T cell therapy in hematology. Turk J Haematol 2015;32:285-294.
  13. Porter DL, Kalos M, Frey NV, et al. Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL. Blood (ASH Annual Meeting Abstracts) 2013;122:abst 873.
  14. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;6:224ra25.


This Article

Current Issue


Indexed/Covered by

Today : 111  /
Total : 181,656